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of breast cancer patients. However, the proportion of patients
who achieve a pathological complete response (pCR) after treat-
ment remains low, reaching 15%–20% in the whole population.
Thus, identifying predictive biomarkers of drug resistance is nec-
essary to select the patients who are most likely to benefit from
chemotherapy. Taxanes (paclitaxel, docetaxel) are potent stabil-
isers of the microtubule cytoskeleton, which functions are tightly
regulated by a panel of MT-associated proteins and mitotic kin-
ases. In the present study, we evaluated whether taxane resist-
ance in breast cancer may be associated with alterations of genes
encoding MT-regulatory proteins.
Material and methods Expression levels of 411 MT-related
genes were analysed from Affymetrix U133 microarray of
breast tumours from three independent multicentered clinical
trials, namely REMAGUS-02 (115 patients), REMAGUS-04
(142 patients) and MD Anderson (133 patients). Only patients
treated with neoadjuvant taxane-based chemotherapy were
included in this study. Expression level of MT-related genes in
tumours was compared with the ability to achieve pCR.
Results and discussions By comparing expression levels of 411
MT-related genes in three independent cohorts of breast can-
cer patients treated with taxane-based neo-adjuvant chemother-
apy, we have identified a total of 94 MT-related genes that
are differentially expressed in tumours with pCR. Among
those, 18 MT-related genes are common to the three cohorts.
Interestingly, all these genes appear as potential prognostic
biomarkers of overall survival. Ongoing studies aim at func-
tionally validating these candidates using siRNA screening in
two different breast cancer cell lines.
Conclusion This study should lead to the identification of
novel predictive biomarkers to select breast cancer patients
who are likely to benefit from taxane-based chemotherapy.
This should also pave the way for future targeted treatments
of chemoresistant breast tumours.
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Introduction Most cancer therapies fail due to the evolution of
therapeutic resistance. Collateral sensitivity, wherein the evolu-
tion of resistance to one drug induces sensitivity to a second, has
been extensively studied to tackle antibiotic resistance through
sequential drug therapies. In cancers, similar evolutionary princi-
ples apply, and trade-offs can occur, whereby the cost of one
resistance mechanism induces a population to be sensitive to an
alternate therapy. Developing new methods to study treatment
resistance through these evolutionary approaches is an impor-
tant, yet understudied, need in the field.
Material and methods To explore the evolutionary dynamics of
treatment resistance, we extended an in vitro model system,
initially in lung cancer cell lines, which enables the measure-
ment of clonal dynamics using semi-random DNA barcode
sequences introduced into cell lines via lentiviral transduction.
One limitation of previous methods was the use of unrealisti-
cally small cell populations (105 – 106), which limits the
genetic heterogeneity that is know to be pervasive in cancer.
We utilised HYPERFlask technology to permit the growth of
large cell populations (108), allowing us to explore drug treat-
ments without the need for serial passaging that artificially
reduces heterogeneity.
Results and discussions By quantitative measurements of
enrichment in molecular barcodes, we identified drug-specific
patterns of selection under gefitinib and trametinib that were
conserved between biological replicates. These quantitative
analyses were indicative of distinct, pre-existing resistance
within the treatment groups, including a small multi-drug
resistant subclone. Further, we used high-throughput drug
screening of the pre- and post-evolution replicates to survey
sensitivities to new drugs. Through mathematical modelling,
we extended these quantitative results to partially determine
fitness landscapes and predict sequences of inhibitors wherein
each sensitises the population to the next.
Conclusion By combining evolutionary principles with mathe-
matical modelling and quantitative measurements of evolution,
we have derived a novel framework to identify collateral sen-
sitivity. In comparison to previous approaches, this framework
better captures the genetic heterogeneity that is intrinsic to
many cancers, and which is known to drive drug resistance.
We expect that this framework will now be used as treatment
strategies for potential verification through in vivo and clinical
studies.
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Introduction Prognosis of patients diagnosed with advanced gas-
tric (GC) cancer is still poor. Personalised medicine for gastric
cancer patients still represents a big challenge. HER2 is the only
actionable target and only trastuzumab (T) is able to improve
median overall survival in selected patients. Lapatinib (L), when
used in I or in II line, was not able to achieve a clinical benefit.
Nevertheless, acquired resistance is an inevitable event.
Material and methods OE 19 and NCI N87, HER2 positive
GC cell lines, were continuously treated with increasing doses
of L and T to obtain resistant clones. Resistance was con-
firmed by MTT viability assays. Genome-wide expression pro-
files of OE 19 and derived clones was evaluated by using
Clariom S microarray from Affymetrix. Data were analysed
using Partek Genomics Suite v6.6 software and Pathway Stu-
dio v10 (Elsevier). Protein expression was analysed by immu-
nofluorescence (IF) and, after subcellular fractionation, by
Western Blot. siRNA of NRF2 was performed. mRNA expres-
sion was performed by qRT PCR
Abstracts
ESMO Open 2018;3(Suppl 2):A1–A463 A217
Published online  29 June 2018
